Department of Medicine

University of Pittsburgh

Ahmad A Tarhini, MD, PhD

photo

Associate Professor of Medicine, Clinical and Translational Science

Department of Medicine

Division of Hematology/Oncology

Office: UPMC Cancer Pavilion, 5150 Centre Ave, Ste 555
Pittsburgh, PA 15232
 
Phone: 412-648-6578
Fax: 412-648-6579
E-mail: tarhiniaa@upmc.edu

Education
BS Biology, American University of Beirut, 1994
MD, Kaunas University of Medicine, 1999
Master of Science, Clinical Research, University of Pittsburgh, School of Medicine, 2006
PhD, Clinical and Translational Science, University of Pittsburgh, School of Medicine, 2011

Training
Internship/Residency, Internal Medicine, University of Pittsburgh Medical Center, 2003
Fellowship, Hematology/Oncology, University of Pittsburgh Cancer Institute, 2006
Clinical Research Training Program, University of Pittsburgh, School of Medicine, 2006

Area of Specialization/Research Interest  
Melanoma
Immunotherapy
Targeted Therapies
Biomarkers
Lung Cancer
 

Profile
Medical School Dean's Honors, 1999;
Resident of the year, Internal Medicine, 2003;
American Board of Internal Medicine (ABIM), certified 2003;
AMGEN Fellowship Award, 2005;
2005 ASCO/AACR workshop, Methods in Clinical Research;
2006 ASCO Foundation Merit Award;
ABIM, Hematology, certified 2006; ABIM, Medical Oncology, certified 2007; The 2009 University of Pittsburgh Cancer Institute Junior Scholar Award in Clinical Research, June 2010; The 2010 Eastern Cooperative Oncology Group (ECOG) Research and Education Foundation Young Investigator Award, June 2010.

Recent Grants
Title: Renewal Skin Spore Project 1, Biomarkers of the Proinflammatory Response and Elements of Immune Suppression
Role: Project Leader
Amount:
Funding Agency: NIH; UPCI Skin Spore; BMS
Start Year: 2013
End Year: 2018
Title: UPCI 11-063, Neoadjuvant Combination Biotherapy with Ipilimumab (3 mg/kg or 10 mg/kg) and High Dose IFN-alfa2b in Patients with Locally/Regionally Advanced/Recurrent Melanoma: A Randomized Safety, Efficacy and Biomarker Study
Role: Principal Investigator
Amount:
Funding Agency: Merck, Bristol-Myers Squibb (Investigator Initiated Clinical/Translational Trial)
Start Year: 2012
End Year: 2014
Title: ECOG-ACRIN E3611, A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-a in Advanced Melanoma
Role: Study Chair
Amount:
Funding Agency: NIH, ECOG-ACRIN
Start Year: 2012
End Year: 2014
Title: UPCI 10-058, A Phase I/II Trial of AMG102 and Erlotinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
Role: Principal Investigator
Amount:
Funding Agency: Amgen (Investigator Initiated Clinical/Translational Trial)
Start Year: 2011
End Year: 2014
Title: SPORE in Lung Cancer
Role: Co-investigator
Amount:
Funding Agency: NIH, Lung Cancer Spore
Start Year: 2011
End Year: 2016
Title: NCI 8628, A Phase II Randomized Multicenter Study Evaluating the Efficacy of Sequential Biotherapy with Aflibercept and High Dose IL-2 in Patients with Inoperable Stage III or Stage IV Melanoma: Efficacy and Biomarker Study
Role: Study Chair
Amount:
Funding Agency: NIH, N01
Start Year: 2011
End Year: 2014
Title: Intergroup E1609, A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma
Role: Study Chair
Amount:
Funding Agency: NIH, ECOG
Start Year: 2011
End Year: 2016
Title: UPCI 07-133, Sentinel Node and Non-Sentinel Lymph Nodes (SLN and non-SLN) Procurement from Melanoma Subjects for Molecular Profiling Analysis
Role: Principal Investigator
Amount:
Funding Agency: Merck (Investigator Initiated Translational Project)
Start Year: 2010
End Year: 2014
Title: UPCI 08-067, Pilot Analysis of the Effects of IFN-alfa2b upon the Molecular Profile of Regional Lymph Nodes in Melanoma Patients with and without Tumor-Involved Sentinel Lymph Nodes
Role: Principal Investigator
Amount:
Funding Agency: Merck (Investigator Initiated Clinical/Translational Trial)
Start Year: 2010
End Year: 2014
Title: UPCI 08-144, Neoadjuvant Anti-CTLA4 Blockade with Ipilimumab in Patients with AJCC Stage IIIB-C (Tx,1-4, N1b,2b, 2c, 3, M0) Melanoma: Immunogenicity And Biomarker Analysis
Role: Principal Investigator
Amount:
Funding Agency: Bristol-Myers Squibb (Investigator Initiated Clinical/Translational Trial)
Start Year: 2010
End Year: 2013

For Pub Med search results, click here.